Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories global COVID-19 Testing-Related Sales ($M) ($M)
Global COVID-19 testing sales peaked at $8,368M in FY2022 ($7,677M in FY2021) and declined to $1,590M in FY2023, $747M in FY2024, and $297M in FY2025.
Latest, FY2025
297
Period ended Dec 31, 2025
Change on a year earlier
-60.2%
747 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Global COVID-19 Testing-Related Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 297 | -60.2% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 747 | -52.9% | SEC Filing (0001628280-26-002982) ↗ |
| FY2023 | Dec 31, 2023 | 1,586 | -81.0% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 8,368 | +9.0% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 7,679 | – | SEC Filing (0001628280-23-001516) ↗ |
Breakdown
What makes up global covid-19 testing-related sales ($m)
Cite this data
StockData. (2026). Abbott Laboratories Global COVID-19 Testing-Related Sales ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-covid-tot
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.